Publication Name	World Journal of Clinical Cases
Manuscript ID	73337
Country	China

Received	2021-11-22 02:56
Peer-Review Started	2021-11-22 02:58
To Make the First Decision
Return for Revision	2022-02-07 08:58
Revised	2022-03-13 01:57
Second Decision	2022-04-15 02:03
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2022-04-15 17:13
Articles in Press	2022-04-15 17:13
Publication Fee Transferred
Edit the Manuscript by Language Editor	2022-05-09 17:12
Typeset the Manuscript	2022-06-07 22:48
Publish the Manuscript Online	2022-06-17 03:19

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Randomized Controlled Trial
Article Title	Sequential chemotherapy and icotinib as first-line treatment for advanced epidermal growth factor receptor-mutated non-small cell lung cancer
Manuscript Source	Unsolicited Manuscript
All Author List	Sheng-Jie Sun, Jin-Di Han, Wei Liu, Zhi-Yong Wu, Xiao Zhao, Xiang Yan, Shun-Chang Jiao and Jian Fang
ORCID	Author(s) ORCID Number Sheng-Jie Sun http://orcid.org/0000-0001-7010-9472 Jin-Di Han http://orcid.org/0000-0002-0790-9802 Wei Liu http://orcid.org/0000-0002-1534-1823 Zhi-Yong Wu http://orcid.org/0000-0002-8763-4449 Xiao Zhao http://orcid.org/0000-0002-8661-1480 Xiang Yan http://orcid.org/0000-0002-3683-474X Shun-Chang Jiao http://orcid.org/0000-0001-8017-5342 Jian Fang http://orcid.org/0000-0003-3697-4563
Funding Agency and Grant Number
Corresponding Author	Shun-Chang Jiao, MD, Chief Doctor, Department of Oncology, The Fifth Medical Center of General Hospital of Chinese People's Liberation Army, No. 100 West Fourth Ring Road, Fengtai District, Beijing 100039, China. jiaosc@vip.sina.com
Key Words	Advanced stage; Chemotherapy; Epidermal growth factor receptor mutation; First-line treatment; Icotinib
Core Tip	The combination of chemotherapy and epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) (concomitant or intercalated) generally showed improved efficacy compared with EGFR-TKI alone as the first-line treatment for advanced non-small cell lung cancer (NSCLC). This study aimed to evaluate the efficacy and safety of chemotherapy followed by icotinib maintenance as first-line treatment for advanced EGFR-mutated NSCLC. Sixty-eight advanced NSCLC patients were randomized 2:3 to administrate icotinib-alone or chemotherapy plus icotinib. Chemotherapy plus icotinib group showed higher progression-free survival than icotinib alone. Our study suggested that a sequential combination of chemotherapy and EGFR-tyrosine kinase inhibitor is feasible for stage IV EGFR-mutated NSCLC patients.
Publish Date	2022-06-17 03:19
Citation	Sun SJ, Han JD, Liu W, Wu ZY, Zhao X, Yan X, Jiao SC, Fang J. Sequential chemotherapy and icotinib as first-line treatment for advanced epidermal growth factor receptor-mutated non-small cell lung cancer. World J Clin Cases 2022; 10(18): 6069-6081
URL	https://www.wjgnet.com/2307-8960/full/v10/i18/6069.htm
DOI	https://dx.doi.org/10.12998/wjcc.v10.i18.6069

Full Article (PDF)	WJCC-10-6069.pdf
Full Article (Word)	WJCC-10-6069.docx
Manuscript File	73337_Auto_Edited_LM-Language editing-Webster J-Clear.docx
Answering Reviewers	73337-Answering reviewers.pdf
Audio Core Tip	73337-Audio core tip.m4a
Biostatistics Review Certificate	73337-Biostatistics statement.pdf
Clinical Trial Registration Statement	73337-Clinical trial registration statement.pdf
Conflict-of-Interest Disclosure Form	73337-Conflict-of-interest statement.pdf
Copyright License Agreement	73337-Copyright license agreement.pdf
Signed Informed Consent Form(s) or Document(s)	73337-Informed consent statement.pdf
Institutional Review Board Approval Form or Document	73337-Institutional review board statement.pdf
Non-Native Speakers of English Editing Certificate	73337-Language certificate.pdf
Peer-review Report	73337-Peer-review(s).pdf
Scientific Editor Work List	73337-Scientific editor work list.pdf
CrossCheck Report	73337-CrossCheck report.pdf